CAMP4 Therapeutics Corporation announced the appointment of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the company on December 10, 2024. These industry veterans will provide strategic guidance on CAMP4’s RNA Actuating platform.
The platform is designed to develop a new class of RNA medicines that upregulate protein coding genes, aiming to restore healthy protein levels across a range of genetic diseases. The addition of Dr. Maraganore and Dr. Meyers is expected to bolster CAMP4's efforts in advancing its pipeline of regulatory RNA-targeting therapeutics.
This move underscores CAMP4's commitment to leveraging top-tier industry knowledge to enhance its innovative approach to genetic medicine. The strategic insights from these advisors are anticipated to support the development of disease-modifying treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.